ADDING ULTRASOUND TO THE TREAT-TO-TARGET STRATEGY SHOWS NO BENEFIT IN ACHIEVEMENT OF REMISSION: RESULTS FROM THE BIODAM COHORT

Author(s):
Sepriano, A.; Ramiro, S.; Landewe, R.; Heijde, D. van der; Ohrndorf, S.; FitzGerald, O.; Backhaus, M.; Larche, M.; Homik, J.; Saraux, A.; Hammer, H.; Terslev, L.; Ostergaard, M.; Burmester, G.; Combe, B.; Dougados, M.; Hitchon, C.; Boire, G.; Dadashova, R.; Paschke, J.; Hutchings, E.; Maksymowych, W.
Published
2017
Publication type
Article / Letter to editor
Date issued
2017-06-30
Language
English
Is part of
Annals of the Rheumatic Diseases (2017), Vol. 76, p. 131-131
hdl
1887/116143
doi
10.1136/annrheumdis-2017-eular.1613